The effect of temozolomide in combination with doxorubicin in glioblastoma cells in vitro

References

• Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; et al. Mgmt Gene Silencing and Benefit from Temozolomide in Glioblastoma. N. Engl. J. Med. 2005, 352, 997–1003.
   PubMed Web of Science ®Google Scholar
• Stupp, R.; Hegi, M. E.; Mason, W. P.; van den Bent, M. J.; Taphoorn, M. J.; Janzer, R. C.; Ludwin, S. K.; Allgeier, A.; Fisher, B.; Belanger, K.; et al. Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase Iii Study: 5-year Analysis of the Eortc-ncic Trial. Lancet Oncol. 2009, 10, 459–466.
   PubMed Web of Science ®Google Scholar
• Carapancea, M.; Cosaceanu, D.; Budiu, R.; Kwiecinska, A.; Tataranu, L.; Ciubotaru, V.; Alexandru, O.; Banita, M.; Pisoschi, C.; Backlund, M. L.; et al. Dual Targeting of Igf-1r and Pdgfr Inhibits Proliferation in High-grade Gliomas Cells and Induces Radiosensitivity in Jnk-1 Expressing Cells. J. Neuro-oncol. 2007, 85, 245–254.
   PubMed Web of Science ®Google Scholar
• Carapancea, M.; Alexandru, O.; Fetea, A. S.; Dragutescu, L.; Castro, J.; Georgescu, A.; Popa-Wagner, A.; Backlund, M. L.; Lewensohn, R.; Dricu, A. Growth Factor Receptors Signaling in Glioblastoma Cells: Therapeutic Implications. J. Neuro-oncol. 2009, 92, 137–147.
   PubMed Web of Science ®Google Scholar
• Popescu, A. M.; Purcaru, S. O.; Alexandru, O.; Dricu, A. New Perspectives in Glioblastoma Antiangiogenic Therapy. Contemp. Oncol (Pozn). 2016, 20, 109–118.
   PubMed Web of Science ®Google Scholar
• Tewey, K. M.; Rowe, T. C.; Yang, L.; Halligan, B. D.; Liu, L. F. Adriamycin-induced DNA Damage Mediated by Mammalian DNA Topoisomerase Ii. Science. 1984, 226, 466–468.
   PubMed Web of Science ®Google Scholar
• Arcamone, F.; Cassinelli, G.; Fantini, G.; Grein, A.; Orezzi, P.; Pol, C.; Spalla, C. Adriamycin, 14-hydroxydaunomycin, a New Antitumor Antibiotic from S. Peucetius Var. Caesius. Biotechnol. Bioeng. 1969, 11, 1101–1110.
   PubMed Web of Science ®Google Scholar
• Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol. Rev. 2004, 56, 185–229.
   PubMed Web of Science ®Google Scholar
• Meadors, M.; Floyd, J.; Perry, M. C. Pulmonary Toxicity of Chemotherapy. Semin. Oncol. 2006, 33, 98–105.
   PubMed Web of Science ®Google Scholar
• You, J. S.; Pan, T. L.; Lee, Y. S. Protective Effects of Danshen (Salvia Miltiorrhiza) on Adriamycin-induced Cardiac and Hepatic Toxicity in Rats. Phytother Res. 2007, 21, 1146–1152.
   PubMed Web of Science ®Google Scholar
• Yilmaz, S.; Atessahin, A.; Sahna, E.; Karahan, I.; Ozer, S. Protective Effect of Lycopene on Adriamycin-induced Cardiotoxicity and Nephrotoxicity. Toxicology. 2006, 218, 164–171.
   PubMed Web of Science ®Google Scholar
• Zhang, R.; Saito, R.; Shibahara, I.; Sugiyama, S.; Kanamori, M.; Sonoda, Y.; Tominaga, T. Temozolomide Reverses Doxorubicin Resistance by Inhibiting P-glycoprotein in Malignant Glioma Cells. J. Neuro-oncol. 2016, 126, 235–242.
   PubMed Web of Science ®Google Scholar
• Ponten, J.; Westermark, B. Properties of Human Malignant Glioma Cells in Vitro. Med. Biol. 1978, 56, 184–193.
   PubMedGoogle Scholar
• Mogosanu, G. D.; Buteică, S. A.; Purcaru, S. O.; Croitoru, O.; Georgescu, A. M.; Serban, F.; Tătăranu, L. G.; Alexandru, O.; Dricu, A. Rationale and in Vitro Efficacy of Ligustrum Vulgare Hydroalcoholic Extract for the Treatment of Brain Tumors. Int. J. Clin. Exp. Pathol. 2016, 9, 8286–8296.
   Web of Science ®Google Scholar
• Ewald, J. A.; Desotelle, J. A.; Wilding, G.; Jarrard, D. F. Therapy-induced Senescence in Cancer. J. Natl. Cancer Inst. 2010, 102, 1536–1546.
   PubMed Web of Science ®Google Scholar
• Weller, M.; Tabatabai, G.; Kästner, B.; Felsberg, J.; Steinbach, J. P.; Wick, A.; Schnell, O.; Hau, P.; Herrlinger, U.; Sabel, M. C. Mgmt Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-intensified Temozolomide Rechallenge in Progressive Glioblastoma: The Director Trial. Clin. Cancer Res. 2015, 21, 2057–2064.
   PubMed Web of Science ®Google Scholar
• Perazzoli, G.; Prados, J.; Ortiz, R.; Caba, O.; Cabeza, L.; Berdasco, M.; Gonzalez, B.; Melguizo, C. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of Mgmt, Mmr, P-glycoprotein and Cd133 Expression. PLoS One. 2015, 10, e0140131.
   PubMed Web of Science ®Google Scholar
• da Hora, C. C.; Schweiger, M. W.; Wurdinger, T.; Tannous, B. A. Patient-derived Glioma Models: From Patients to Dish to Animals. Cells. 2019, 8, pp. 1177.
   Web of Science ®Google Scholar
• Ben-David, U.; Beroukhim, R.; Golub, T. R. Genomic Evolution of Cancer Models: Perils and Opportunities. Nat. Rev. Cancer. 2019, 19, 97–109.
   PubMed Web of Science ®Google Scholar
• Yool, A. J.; Ramesh, S. Molecular Targets for Combined Therapeutic Strategies to Limit Glioblastoma Cell Migration and Invasion. Front. Pharmacol. 2020, 11, 358.
   PubMed Web of Science ®Google Scholar
• Gilbert, M. R.; Wang, M.; Aldape, K. D.; Stupp, R.; Hegi, M. E.; Jaeckle, K. A.; Armstrong, T. S.; Wefel, J. S.; Won, M.; Blumenthal, D. T.; et al. Dose-dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase Iii Clinical Trial. J. Clin. Oncol. 2013, 31, 4085–4091.
   PubMed Web of Science ®Google Scholar
• Alexandru, O.; Sevastre, A. S.; Castro, J.; Artene, S. A.; Tache, D. E.; Purcaru, O. S.; Sfredel, V.; Tataranu, L. G.; Dricu, A. Platelet-derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines. Int. J. Mol. Sci. 2019, 20, pp. 4663.
   Web of Science ®Google Scholar
• Alexandru, O.; Dragutescu, L.; Tataranu, L.; Ciubotaru, V.; Sevastre, A.; Georgescu, A. M.; Purcaru, O.; Danoiu, S.; Backlund, L. M.; Dricu, A. Helianthin Induces Antiproliferative Effect on Human Glioblastoma Cells in Vitro. J. Neuro-oncol. 2011, 102, 9–18.
   PubMed Web of Science ®Google Scholar
• Alexandru, O.; Horescu, C.; Sevastre, A. S.; Cioc, C. E.; Baloi, C.; Oprita, A.; Dricu, A. Receptor Tyrosine Kinase Targeting in Glioblastoma: Performance, Limitations and Future Approaches. Contemp. Oncol (Pozn). 2020, 24, 55–66.
   PubMed Web of Science ®Google Scholar
• Sevastre, A.-S.; Horescu, C.; Carina Baloi, S.; Cioc, C. E.; Vatu, B. I.; Tuta, C.; Artene, S. A.; Danciulescu, M. M.; Tudorache, S.; Dricu, A. Benefits of Nanomedicine for Therapeutic Intervention in Malignant Diseases. Coatings. 2019, 9, 628.
   Web of Science ®Google Scholar
• Villodre, E. S.; Kipper, F. C.; Silva, A. O.; Lenz, G.; Lopez, P. Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells. Mol. Neurobiol. 2018, 55, 4185–4194.
   PubMed Web of Science ®Google Scholar
• Du, K.; Xia, Q.; Heng, H.; Feng, F. Temozolomide-doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy. ACS Appl. Mater. Interfaces. 2020, 12, 31, 34599–34609.
   Web of Science ®Google Scholar